Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 15:6:143-52.
doi: 10.2147/tcrm.s5582.

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

Linda L Hushaw  1 , Ray Sawaqed, Ghaleb Sweis, Jori Reigle, Anjali Gopal, Daniel Brandt, Nadia Sweis, James Curran, Timothy B Niewold, Nadera J Sweiss
Affiliations

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

Linda L Hushaw et al. Ther Clin Risk Manag. .

Abstract

Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.

Keywords: IL-6; methotrexate; rheumatoid arthritis; tocilizumab.

PubMed Disclaimer

References

    1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25. - PubMed
    1. Arthritis F. Rheumatoid arthritis fact sheet. 2009. http://www.arthritis.org/media/newsroom/media-kits/Rheumatoid_Arthritis_...
    1. Olivieri I, Palazzi C, Peruz G, Padula A. Management issues with elderly-onset rheumatoid arthritis: an update. Drugs Aging. 2005;22:809–822. - PubMed
    1. Jackson CG, Williams HJ. Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection. Drugs. 1998;56:337–344. - PubMed
    1. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65:661–694. - PubMed